On April 1, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Netherlands Synthon B.V. (hereinafter referred to as " Synthon ") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of hyperphosphatemia (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commercialization of the product in China.

This product is an oral phosphate binder,which has been marketed in many European countries with the indication of Hyperphosphatemia in pediatric and adults patients with CKD.There are no products with the same formulation approved in China to date, therefore this product will be submitted as the imported drug with exclusive formulation. Compared with the formulations available in Chinese market, this product is more suitable for children and patients with dysphagia.

Hyperphosphatemia is a common complication in patients with chronic kidney disease (CKD). Oral phosphate binders are an important treatment measure for hyperphosphatemia in patients withCKD.According to Fortune Business Insights, the global hyperphosphatemia treatment market size was USD 2.36 billion in 2020, andthe drug with this API accounted for a dominant share.

This cooperation with Synthon means the further expansion of Beimei productsline and expands the treatment field to chronic kidney disease.

    About Synthon

Synthon B.V., founded in 1991 and headquartered in Netherlands, is an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic and hybrid medicines for patients around the world. Synthon today has laboratories, offices, and production plants in nine countries around the world and employs about 1,600 staff worldwide. Currently its products are approved by regulatory agencies in around 100 countries and marketed through strategic partnerships with the largest pharmaceutical companies in the world, and - in dedicated areas - through direct sales. The products therapeutic areas including oncology, urinary system, cardiovascular, central nervous system, etc. For more information, go to www.synthon.com

Beimei pharmaceutical focuses on the field of pediatric prescription medicines in China, aiming to become a new pharmaceutical enterprise integrating research and development, licensing in, production, and sales. Beimei takes in-house research and development and international licensing-in as its strategic direction. At present, the product pipeline covers the respiratory system, anti-infection, nervous system, digestive system, and other fields. Beimei is committed to providing convenient, accurate, excellent taste and high-quality products for Chinese pediatric patients. For more information, go to www.beimeiyaoye.com